Pfizer Buying Spree Continues With $5.4B Hematology Deal

Pfizer Buying Spree Continues With $5.4B Hematology Deal
The Pfizer logo is displayed on the exterior of a former Pfizer factory, on May 4, 2014, in Brooklyn, New York. (AP Photo/Mark Lennihan, File)

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets for treating sickle cell disease.

The latest deal follows Pfizer’s $11.6 billion acquisition of Biohaven, which the companies announced in May, and a $6.7 billion acquisition of Arena Pharmaceuticals announced last December.

Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus.

Pfizer Inc.’s top-selling COVID-19 vaccine and treatment have left the New York City drugmaker flush with cash to spend on an acquisition spree. The vaccine and treatment brought in more than $16 billion combined just in the recently completed second quarter.

Pfizer’s vaccine, Comirnaty, rang up nearly $37 billion in sales last year alone, but those sales are expected to fade in a few years. Pfizer also faces over the next decade the loss of patent protection for key products like Eliquis for preventing blood clots and strokes.

The company plans to have about $25 billion in sales by 2030 come from new business developments.

Aamir Malik, the company’s chief business innovation officer, told analysts recently that Pfizer was “leaving very few stones unturned” in looking for expansion opportunities. Malik said Pifzer was looking for deals that will speed up growth in the back half of the decade and can add substantial value either scientifically or commercially.

“I think we’re very excited about the opportunities that are ahead of us and the flexibility that our balance sheet gives us to pursue those,” he said during a call to discuss second-quarter results.

Aside from Oxbryta, Global Blood Therapeutics also is developing some other treatments for sickle cell disease.

Oxbryta sales were about $195 million last year, but Pfizer said it plans to speed up distribution of the drug to parts of the world most impacted by the disease.

Sickle cell disease is an inherited blood disorder that can lead to bouts of acute pain and organ damage. It occurs particularly among people of African descent.

Pfizer will pay $68.50 per share in cash for each share of Global Blood Therapeutics. That represents a premium of nearly 43% from the stock’s closing price of $47.99 on Aug. 4, the day before The Wall Street Journal reported that Pfizer was in advanced talks on a deal.

Both companies’ boards have approved the deal, which still needs regulatory approval and approval from GBT shareholders. The companies say the deal could close as soon as the fourth quarter.

Shares of Global Blood Therapeutics Inc., based just outside San Francisco, rose more than 4% to $66.68 before the opening bell. Shares of Pfizer were essentially flat.

___

Follow Tom Murphy on Twitter: @thpmurphy

A+
a-
  • Pfizer
  • In The News

    Health

    Voting

    Business

    Wall Street Points to Losses as Trump’s Tariff Deadline Nears

    (AP) — Wall Street is pointing to a lower open Monday as the Trump administration steps up pressure on trading... Read More

    (AP) — Wall Street is pointing to a lower open Monday as the Trump administration steps up pressure on trading partners to quickly make deals before a Wednesday deadline. The U.S. will warn trading partners that higher tariffs could kick in Aug. 1. Futures for the S&P... Read More

    Analysis Shows Trump's Tariffs Would Cost US Employers $82.3B

    WASHINGTON (AP) — An analysis finds that a critical group of U.S. employers would face a direct cost of $82.3... Read More

    WASHINGTON (AP) — An analysis finds that a critical group of U.S. employers would face a direct cost of $82.3 billion from President Donald Trump’s current tariff plans, a sum that could be potentially managed through price hikes, layoffs, hiring freezes or lower profit margins. The analysis... Read More

    June 20, 2025
    by Dan McCue
    Justices Open Door to Multiple-Venue Challenges to E-Cigarette Rules

    WASHINGTON — The Supreme Court on Friday held that retailers who would sell a new tobacco product if not for... Read More

    WASHINGTON — The Supreme Court on Friday held that retailers who would sell a new tobacco product if not for the Food and Drug Administration’s rejection of the product, can sue to seek judicial review of the agency’s decision. The 7-2 ruling by the court in... Read More

    Hit by Trump Trade Wars, US Economy Falls 0.2% in First Quarter, an Upgrade From Initial Estimate

    WASHINGTON (AP) — The U.S. economy shrank at a 0.2% annual pace from January through March, the first drop in... Read More

    WASHINGTON (AP) — The U.S. economy shrank at a 0.2% annual pace from January through March, the first drop in three years, as President Donald Trump’s trade wars disrupted business, the government said Thursday in a slight upgrade of its initial estimate. First-quarter growth was brought down by... Read More

    DC Mayor Seeks Business-Friendly Policies to Spark Growth Amid Loss of up to 40,000 Federal Jobs

    WASHINGTON (AP) — With the nation's capital facing a pair of overlapping budget crises, D.C. Mayor Muriel Bowser has unveiled a budget... Read More

    WASHINGTON (AP) — With the nation's capital facing a pair of overlapping budget crises, D.C. Mayor Muriel Bowser has unveiled a budget proposal that bets heavily on business-friendly policies designed to boost investment and move the city away from dependence on a dwindling number of federal jobs. “We have... Read More

    A Wave of New Owners Brings Fresh Energy to Independent Bookselling

    NEW YORK (AP) — Amber Salazar is the kind of idealist you just knew would end up running a bookstore... Read More

    NEW YORK (AP) — Amber Salazar is the kind of idealist you just knew would end up running a bookstore — a lifelong reader who felt angered “to the core” as she learned of book bans around the country. A resident of Colorado Springs, Colorado, Salazar last... Read More

    News From The Well
    scroll top